{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T-cell+lymphocyte+responses&page=4", "query": { "intervention": "T-cell lymphocyte responses", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 281, "total_pages": 29, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T-cell+lymphocyte+responses&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T-cell+lymphocyte+responses&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T04:31:27.868Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04397861", "title": "T Cell Memory Fuels the Innate Response in Chronic CF Lung Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cystic Fibrosis" ], "interventions": [], "intervention_types": [], "sponsor": "National Jewish Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2015-05-06", "completion_date": "2021-11-01", "has_results": false, "last_update_posted_date": "2022-09-29", "last_synced_at": "2026-10-06T04:31:27.868Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04397861" }, { "nct_id": "NCT06075524", "title": "Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Locally Advanced Lung Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Melanoma", "Metastatic Lung Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Stage III Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2015-06-15", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-06T04:31:27.868Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06075524" }, { "nct_id": "NCT05956041", "title": "Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous T Cell Lymphoma", "Fungoides Mycosis Sezary Syndrome" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Mogamulizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2023-12-06", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-06T04:31:27.868Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05956041" }, { "nct_id": "NCT03989466", "title": "Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent T-Cell Prolymphocytic Leukemia", "T-Cell Prolymphocytic Leukemia" ], "interventions": [ { "name": "Alemtuzumab", "type": "BIOLOGICAL" }, { "name": "Itacitinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2020-01-15", "completion_date": "2024-09-24", "has_results": false, "last_update_posted_date": "2024-10-10", "last_synced_at": "2026-10-06T04:31:27.868Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03989466" }, { "nct_id": "NCT03117751", "title": "Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Erwinase®", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Nelarabine", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Asparaginase Erwinia chrysanthemi (recombinant)-rywn", "type": "DRUG" }, { "name": "Calaspargase Pegol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 790, "start_date": "2017-03-29", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-06T04:31:27.868Z", "location_count": 7, "location_summary": "Palo Alto, California • San Diego, California • Peoria, Illinois + 4 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03117751" }, { "nct_id": "NCT05054088", "title": "ImmuneSense COVID-19 Variant Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Covid19" ], "interventions": [ { "name": "T-Detect COVID test", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Adaptive Biotechnologies", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 203, "start_date": "2021-10-12", "completion_date": "2022-07-28", "has_results": false, "last_update_posted_date": "2022-12-07", "last_synced_at": "2026-10-06T04:31:27.868Z", "location_count": 15, "location_summary": "Phoenix, Arizona • Fullerton, California • Los Angeles, California + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Modesto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05054088" }, { "nct_id": "NCT05243862", "title": "Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "PolyPEPI1018", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Treos Bio Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2022-06-02", "completion_date": "2025-01-14", "has_results": true, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-06T04:31:27.868Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05243862" }, { "nct_id": "NCT07284433", "title": "Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma Diffuse Large B-cell", "Leukemia and Lymphoma", "Leukemia Relapse", "Lymphoma Receiving CAR-T Therapy" ], "interventions": [ { "name": "Cyclophosphamide (Non-IMP, Lymphodepletion)", "type": "OTHER" }, { "name": "Fludarabine (Non-IMP, Lymphodepletion)", "type": "OTHER" }, { "name": "Allo-QuadCAR01-T", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "AvenCell Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 178, "start_date": "2026-01-06", "completion_date": "2029-11-02", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-06T04:31:27.868Z", "location_count": 5, "location_summary": "Chicago, Illinois • Evanston, Illinois • Providence, Rhode Island + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07284433" }, { "nct_id": "NCT03680677", "title": "Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Leukemia, Acute", "MDS" ], "interventions": [ { "name": "Bone Marrow or Peripheral Blood Graft (BMT)", "type": "PROCEDURE" }, { "name": "Cancer-directed Therapy or Best Supportive Care", "type": "OTHER" }, { "name": "Frailty Assessment", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 20, "start_date": "2018-09-21", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-06T04:31:27.868Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03680677" }, { "nct_id": "NCT00076037", "title": "Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "HIV CTL MEP administered with RC529-SE adjuvant", "type": "BIOLOGICAL" }, { "name": "GM-CSF", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 96, "start_date": "2004-04", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-10-06T04:31:27.868Z", "location_count": 7, "location_summary": "Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00076037" } ] }